Stay informed
MAPS practices the principle of Open Science, Open Books, transparently sharing what we learn. Through our publications, we seek to Be the Bridge, building common knowledge between the medical, the mystical, the marginalized, and the mainstream.
Are you a member of the media? Visit our newsroom.
MAPS PBC Publishes Results of Successful Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD
September 13, 2023
FOR IMMEDIATE RELEASE: September 14, 2023 Results of the second, confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder, MAPP2, have been published in Nature Medicine. MAPP2 …
MAPS Launches Online Video Sessions from Psychedelic Science 2023 with The Virtual Trip
August 30, 2023
The Multidisciplinary Association for Psychedelic Studies (MAPS) has begun publishing a collection of content from the highly acclaimed Psychedelic Science 2023 conference. PS2023: The Virtual Trip brings …
MAPS Receives $5 Million Grant from the Steven & Alexandra Cohen Foundation
June 22, 2023
MAPS and the Steven & Alexandra Cohen Foundation Partner to Support the Development of Psychedelic-Assisted Therapies FOR IMMEDIATE RELEASE: June 22, 2023 TheMultidisciplinary Association for Psychedelic …
MAPS-Sponsored Global Psychedelic Survey Gathers Data for a Crucial View into Psychedelic Use
May 22, 2023
FOR IMMEDIATE RELEASE: May 22, 2023 The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the launch of the Global Psychedelic Survey. Co-sponsored by MAPS, SABI Mind, Mind Medicine …
STATEMENT: MAPS-Funded Phase 3 Research Reports Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for PTSD
April 5, 2023
FOR IMMEDIATE RELEASE: April 5, 2023 MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), announced preliminary findings …
Big, if True: Did Australia Legalize MDMA and Psilocybin?
February 27, 2023
Distinctions in Australian MDMA and Psilocybin Policy The Therapeutic Goods Administration (TGA) in Australia recently announced a new policy allowing for the limited use of psychedelic-assisted therapies …
Statement: Psychedelic-Assisted Therapies Allowed in Australia Through Special Access Scheme
February 3, 2023
FOR IMMEDIATE RELEASE: February 3, 2023 The Therapeutic Goods Administration (TGA) in Australia announced today that they will permit limited use of certain psychedelic-assisted therapies for the treatment …
Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial
January 5, 2023
The world’s most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
Jury Finds in Favor of Plaintiffs in Trial on Harm Reduction and Medical Responsibility
December 1, 2022
On November 30, 2022, the jury in CARLA GATLIN, et al. vs DO LAB INC, et al. found in favor of the plaintiffs on the issues of medical responsibility and damages related to the death of a 20-year old woman …
A Psychedelic Caucus is Coming to Congress
November 17, 2022
November 17, 2022 MAPS celebrates the formation of the Congressional Psychedelics Advancing Clinical Treatments (PACT) Caucus, announced today. Led by Representatives Lou Correa (D-CA) and Jack Bergman …
Second MAPS-Sponsored Phase 3 Trial of MDMA-Assisted Therapy for PTSD Completed
November 17, 2022
FOR IMMEDIATE RELEASE: November 17, 2022 MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase …
MAPS Analysis of Colorado’s Natural Medicine Health Act: Reviewing Proposition 122/Measure 58
October 26, 2022
MAPS’ Policy Values Over the last three years since MAPS published our Considerations For the Regulation and Decriminalization of Psychedelic Substances statement, multiple policy approaches to psychedelics …